利拉鲁肽联合不同药物治疗对糖尿病患者胰岛β细胞功能、糖脂代谢的影响  

Effects of Liraglutide Combined with Different Drugs on Pancreaticβ-Cell Function and Glucose-Lipid Metabolism in 206 Diabetic Patients

作　　者：陈小铭[1] CHEN Xiaoming(Department of Pharmacy,The Third People's Hospital of Taizhou,Taizhou,Jiangsu 225321,China)

机构地区：[1]泰州市第三人民医院药剂科,江苏泰州225321

出　　处：《中国医药指南》2025年第11期109-112,共4页Guide of China Medicine

摘　　要：目的对比利拉鲁肽联合盐酸二甲双胍缓释片和利拉鲁肽联合达格列净片两种不同治疗方法对糖尿病患者胰岛β细胞功能、糖脂代谢的影响。方法选取2021年9月至2024年6月期间在泰州市第三人民医院药剂科接受治疗的206例2型糖尿病患者作为研究对象。按照所采用的药物治疗方案不同,将这些患者均分为对照组与观察组,每组103例,对照组患者接受利拉鲁肽联合盐酸二甲双胍缓释片进行治疗,观察组患者接受利拉鲁肽联合达格列净片进行治疗。对比两组患者血糖代谢指标[餐后2 h血糖(2 h PBG)、空腹状态下的血糖(FBG)、糖化血红蛋白(HbA1c)]、血脂代谢指标[视黄醇结合蛋白4(RBP4)、11脱氢血栓素B2(11-D H-TXB2)、脂联素(ADPN)]、胰岛β细胞功能[空腹胰岛素(FINS)、胰岛β细胞功能(HOMA-β)、胰岛素抵抗指数(HOMA-IR)]及不良反应发生情况。结果治疗之后,观察组2 h PBG为(8.96±1.08),低于对照组的(9.65±1.24)(P<0.05),但组间其他两项代谢指标对比,差异无统计学意义(P>0.05)。治疗之后,观察组ADPN为(11.07±0.68),低于对照组的(12.07±1.64)(P<0.05),但组间其他代谢指标比较,差异无统计学意义(P>0.05)。治疗之后,观察组HOMA-β水平是(69.50±8.43)、HOMA-IR水平是(1.86±0.32),低于对照组(P<0.05),但组间FINS比较,差异无统计学意义(P>0.05)。两组患者不良反应总发生率对比,差异无统计学意义(P>0.05)。结论利拉鲁肽联合盐酸二甲双胍缓释片在提升胰岛β细胞功能方面优势较为显著,有助于长期血糖控制。利拉鲁肽联合达格列净片则在降低胰岛素抵抗方面表现更突出,有效改善整体代谢状况,二者均为糖尿病治疗的有效策略,且安全性较高。Objective To compare the effects of liraglutide combined with metformin hydrochloride sustained-release tablets and liraglutide combined with dapagliflozin tablets on pancreaticβ-cell function and glucose-lipid metabolism in diabetic patients.Methods A total of 206 patients with type 2 diabetes who were admitted to the Department of Pharmacy of the Third People's Hospital of Taizhou from September 2021 to June 2024 were selected.According to different drug treatments,the patients were divided into the control group and the observation group,103 cases in each group,the control group patients were treated with liraglutide combined with metformin hydrochloride extended-release tablets,and the patients in the observation group were treated with liraglutide combined with dapagliflozin tablets.Compare the two groups of patients regarding the following aspects:glycemic metabolism indicators[2-hour postprandial blood glucose(2 h PBG),fasting blood glucose(FBG),glycated hemoglobin(HbA1c)],lipid metabolism indicators[retinol-binding protein 4(RBP4),11-dehydro thromboxane B2(11-D H-TXB2),adiponectin(ADPN)],pancreaticβ-cell function[fasting insulin(FINS),homeostasis model assessment ofβ-cell function(HOMA-β),homeostasis model assessment of insulin resistance(HOMA-IR)],and the incidence of adverse reactions.Results After treatment,the 2 h PBG in the observation group was(8.96±1.08),lower than the(9.65±1.24)in the control group(P<0.05),however,other two metabolic indicators showed no significant difference between groups(P>0.05).After treatment,the ADPN in the observation group was(11.07±0.68),lower than the(12.07±1.64)in the control group(P<0.05),however,other metabolic indicators showed no significant difference between groups(P>0.05).After treatment,the HOMA-βlevel in the observation group was(69.50±8.43),and the HOMA-IR level was(1.86±0.32),lower than those in the control group(P<0.05),however,the FINS comparison showed no significant difference between groups(P>0.05).The overall incidence of adverse reactions i

关 键 词：糖尿病 利拉鲁肽 盐酸二甲双胍缓释片 胰岛素 糖代谢 

分 类 号：R587.1[医药卫生—内分泌]